supporting image

Epilepsy

Epilepsy is a common neurological disorder affecting approximately 4-10 in every 1,000 people.1 Labcorp offers one of the most comprehensive suites of epilepsy tests and services to help you provide patients and families with the answers they need.

    From initial screening through diagnosis and follow up, Labcorp supports the continuum of your patients’ care with:

    • Autoimmune epilepsy antibody testing
    • Genetic testing (NGS) panels
    • Genetic counselling services
    • Therapeutic drug level testing
    • Biochemical and metabolic testing

    Genetic Testing (NGS) Panels

    Approximately 70-80% of epilepsy cases are believed to be due to one or more genetic factors.2,3 Testing for epilepsy-related genes may be helpful for clarifying diagnosis and prognosis, selecting optimal treatments, and revealing information for family planning.4 Labcorp offers two genetic testing options: Clinical Epilepsy NGS Panel (630550): 46 genes, and Comprehensive Epilepsy NGS (630268): 811 genes.

    Learn More (Clinical) Learn More (Comprehensive)

    Autoimmune Epilepsy Evaluation Panel (505490)

    This test provides an evaluation of possible autoantibodies in patients with suspected autoimmune epilepsy, and optimizes the likelihood of detecting neuronal specific autoantibodies. 
     


     

    Learn More

    Genetic Counseling Resources

    Genetic counseling services are available to help patients understand their risk and results from NGS panels. Patients can schedule an appointment by calling 855-GC-CALLS or 855-422-2557.

    Therapeutic drug level testing

    Labcorp offers a broad catalog of tests for assessing epilepsy drug levels in patients.

    Test No. 

    Drug Name 

    Test No. 

    Drug Name 

    007419 

    Carbamazepine, Serum or Plasma 

    716936 

    Levetiracetam, Serum or Plasma 

    716803 

    Carbamazepine-10,11 Epoxide 

    716928 

    Oxcarbazepine, Serum or Plasma 

    167129 

    HLA B* 15:02, Carbamazepine Sensitivity 

    007823 

    Phenobarbital, Serum or Plasma 

    702735 

    Cenobamate (Xcopri), Plasma 

    007401 

    Phenytoin, Serum or Plasma 

    007443 

    Ethosuximide, Serum or Plasma 

    809623 

    Pregabalin, Urine 

    716530 

    Felbamate, Serum or Plasma 

    007856 

    Primidone, Serum or Plasma 

    716811 

    Gabapentin, Serum or Plasma 

    716285 

    Topiramate, Serum or Plasma 

    007012 

    Lacosamide 

    007260 

    Valproic Acid, Serum or Plasma 

    716944 

    Lamotrigine, Serum or Plasma 

    007915 

    Zonisamide, Serum or Plasma 
    702690 Cannabidiol (CBD), MS, Serum or Plasma  790500 Clobazam, serum or plasma   
    071712  Clonazepam, serum or plasma  811903 Clonazepam (Urine)
    007989 Diazepam, serum or plasma   702790  Eslicarbazepine Acetate, Immunoassay, Serum or Plasma   
    808465 Lorazepam, serum or plasma   808025 Lorazepam (urine)  
    284191 Rufinamide, serum or plasma  842104 Tiagiapine, serum or plasma   
    808315  Vigabatrin, serum or plasma  

     

    Biochemical and metabolic testing

    Labcorp has a full suite of metabolic and biochemical genetic testing to help evaluate and monitor epilepsy patients, such as creatine, neopterin/tetrahydrobiopterin and neurotransmitter metabolites. Download our epilepsy brochure for a complete list.

    References

    1. Epilepsy. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/epilepsy. June 20, 2019. Accessed 1/26/2021. 
    2. Hildebrand MS, Dahl HH, Damiano JA, et al. Recent advances in the molecular genetics of epilepsy. J Med Genet. 2013; 50:271–279.
    3. Myers CT, Mefford HC. Advancing epilepsy genetics in the genomic era. Genome Medicine. 2015;7:91.
    4. Poduri A, Sheidley BR, Shostak S, Ottman R. Genetic Testing in the Epilepsies-Developments and Dilemmas. Nat Rev Neurol. 2014 May;10(5):293-299. PubMed 24733164